Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.
Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.
James Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.
Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discusses OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.
Amy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.
Brian Culley, CEO of Lineage Cell Therapeutics, sits down with Neil to discuss his company’s efforts to develop off-the-shelf cell therapies to treat degenerative retinal disease, spinal cord injury, and cancer.
Craig Laferrière head of vaccine development for Novateur Ventures, joins Neil to discuss the relative strengths and weaknesses of the different COVID-19 vaccines in use and in development.
Rachel Kuperman, CEO of Eysz, sits down with Neil to discuss her company’s efforts to develop a digital health platform using passive eye-movements as input to measure, diagnose, and predict neurological disease starting with epilepsy.
Anthony DePasqua, CEO of EnClear Therapies, sits down with Neil to discuss the company’s technology in development to remove toxic proteins from cerebrospinal spinal fluid to treat patients with ALS and other neurodegenerative conditions.
Arvind Gupta, founder of IndieBio and co-lead of the engineering biology practice at the venture capital firm Mayfield, and Po Bronson, author and managing director and partner at IndieBio, sit down with Neil to discuss their new book Decoding the World, IndieBio, and the future of biotech.
About ten years ago, futurist Sonia Arrison in her book “100 Plus” explored the coming age of longevity and the broad impacts it would have. Now, as a venture investor, she’s backing companies that are positively impacting longevity through her 100 Plus Capital. In this episode, Neil talks to Arrison about the area of longevity, her investment approach, and how the field has evolved.
Greg Simon, former president of the Biden Cancer Initiative and former executive director of the White House Cancer Moonshot Task Force, discusses his long career in healthcare that has cut across the government, nonprofit, and private sectors. His work has extended from FasterCures, which has sought to build a patient-centric system to accelerate the development of therapies to the healthcare investment platform Poliwogg, which sought to democratize healthcare investing. Neil speaks to Greg abo...
In November, voters approved a new $5.5 billion bond measure that extends the life of the California Institute for Regenerative Medicine. The measure passed with far less fanfare than the original proposition that established the institute in the midst of a national controversy over embryonic stem cell research. With the passage of the new measure, the institute is expanding its work in emerging areas of regenerative medicine including cell and gene therapies and increasing its focus on translat...
